tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MetaVia Extends Phase 1 Trial for Obesity Drug

Story Highlights
MetaVia Extends Phase 1 Trial for Obesity Drug

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

MetaVia ( (MTVA) ) has shared an announcement.

On August 6, 2025, MetaVia Inc. announced an extension of the 48 mg multiple ascending dose cohort in its Phase 1 clinical trial of DA-1726 for obesity treatment, from 4 to 8 weeks, administering a fifth weekly dose to the first patient. This extension aims to assess early efficacy, patient safety, and tolerability with longer-term exposure, and to explore the non-titrated maximum tolerated dose. Previously reported data showed promising weight loss and safety profiles, suggesting DA-1726 may offer a superior tolerability profile compared to existing GLP-1 therapies. The trial’s top-line data is expected in the fourth quarter of 2025, potentially positioning DA-1726 more strongly against current treatments.

The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

Spark’s Take on MTVA Stock

According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.

MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.

To see Spark’s full report on MTVA stock, click here.

More about MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, aimed at superior body weight loss compared to selective GLP1R agonists.

Average Trading Volume: 295,661

Technical Sentiment Signal: Sell

Current Market Cap: $11.75M

See more insights into MTVA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1